• Fri news: Gilead withdraws bladder cancer drug. Amgen and Intercept PDUFA date pushback. CVS replaces CEO. Supernus depression trial. AbbVie Parkinson’s approval. See more on our front page

Being an Alkermes Shareholder…

anonymous

Guest
…is living every day of your life expecting disappointment. Honestly though, Pops is a slick talker and all, but if he were a TBM he would have been put on a PIP like 4 years ago.
 




Stock price is such a disappointment. Our leadership touts their successes and raves about revenues, yet all we see is an ongoing price drop. This is what we get for having an in-bred BOD continuing to support Pops. ENOUGH IS ENOUGH!
 




Similar threads

Replies
4
Views
1K
Alkermes
anonymous
Replies
1
Views
747
Replies
8
Views
4K
Replies
14
Views
3K